Lecanemab (Leqembi®) and donanemab (Kisunla®) are two new FDA-approved drugs, administered intravenously, that can slow cognitive decline in people diagnosed with early-stage Alzheimer’s. While not a cure, they can slow...
Topic: Diseases & Conditions
